Timing the Stem Cell Opportunity
Executive Summary
Companies are drawing parallels between the monoclonal antibody industry and stem cells, and they are trying to strike a balance between gaining a stake in a field with tremendous potential without being too early. Stem cells have the potential to treat some of the largest degenerative diseases in the cardiovascular, neurological, orthopedic segments--markets worth in the double digit billions, according to a recent report on Tissue Engineering, issued by Medtech Insight. No company wants to be left behind.
You may also be interested in...
Multiple Paths of Convergence in Tissue Engineering
A collaboration within Carnegie Mellon is using ink-jet printing technology to create spatial patterns of growth factors, and in turn using them to influence the development of stem cells in vitro. The technology could provide a better means of harnessing the power of growth factor biology in regenerative medicine. The team is also using it to begin to develop rudimentary artificial bone-tendon-muscle constructs for eventual clinical use.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.